Starpharma Holdings Limited (ASX:SPL)

Market Cap	292.70M +614.3%
Revenue (ttm)	14.58M +250.6%
Net Income	-3.23M
EPS	-0.01
Shares Out	421.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,622,498
Average Volume	1,522,173
Open	0.6900
Previous Close	0.6950
Day's Range	0.6700 - 0.7050
52-Week Range	0.0820 - 0.7050
Beta	0.48
RSI	81.44
Earnings Date	May 18, 2026

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhance...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 40
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SPL

Financial Performance

In fiscal year 2025, Starpharma Holdings's revenue was 5.85 million, a decrease of -40.04% compared to the previous year's 9.76 million. Losses were -9.99 million, 22.4% more than in 2024.